(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of -11.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Septerna's revenue in 2026 is $98,882,000.On average, 12 Wall Street analysts forecast SEPN's revenue for 2026 to be $4,572,707,113, with the lowest SEPN revenue forecast at $2,438,123,650, and the highest SEPN revenue forecast at $5,783,273,733. On average, 12 Wall Street analysts forecast SEPN's revenue for 2027 to be $3,894,537,750, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $6,028,327,705.
In 2028, SEPN is forecast to generate $3,189,902,558 in revenue, with the lowest revenue forecast at $1,601,019,282 and the highest revenue forecast at $4,410,971,492.